PMID- 31455405
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Aug 28
TI  - Applicability of adipose-derived mesenchymal stem cells in treatment of patients 
      with type 2 diabetes.
PG  - 274
LID - 10.1186/s13287-019-1362-2 [doi]
LID - 274
AB  - Type 2 diabetes mellitus (T2DM) is mainly characterized by insulin resistance 
      (IR) and impaired insulin secretion. The chronic inflammatory process contributed 
      to IR and could also hamper pancreatic beta cell function. However, currently 
      applied treatment cannot reverse beta cell damage or alleviate inflammation. 
      Mesenchymal stem cells (MSCs), the cell-based therapy for their self-renewable, 
      differentiation potential, and immunosuppressive properties, have been 
      demonstrated in displaying therapeutic effects in T2DM. Adipose-derived MSCs 
      (AD-MSCs) attracted more attention due to less harvested inconvenience and 
      ethical issues commonly accompany with bone marrow-derived MSCs (BM-MSCs) and 
      fetal annex-derived MSCs. Both AD-MSC therapy studies and mechanism explorations 
      in T2DM animals presented that AD-MSCs could translate to clinical application. 
      However, hyperglycemia, hyperinsulinemia, and metabolic disturbance in T2DM are 
      crucial for impairment of AD-MSC function, which may limit the therapeutical 
      effects of MSCs. This review focuses on the outcomes and the molecular mechanisms 
      of MSC therapies in T2DM which light up the hope of AD-MSCs as an innovative 
      strategy to cure T2DM.
FAU - Qi, Yicheng
AU  - Qi Y
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, RenJi 
      Hospital, School of Medicine, Shanghai Jiaotong University, 160# Pujian Road, 
      Pudong, Shanghai, 200127, China.
FAU - Ma, Jing
AU  - Ma J
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, RenJi 
      Hospital, School of Medicine, Shanghai Jiaotong University, 160# Pujian Road, 
      Pudong, Shanghai, 200127, China.
FAU - Li, Shengxian
AU  - Li S
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, RenJi 
      Hospital, School of Medicine, Shanghai Jiaotong University, 160# Pujian Road, 
      Pudong, Shanghai, 200127, China.
FAU - Liu, Wei
AU  - Liu W
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, RenJi 
      Hospital, School of Medicine, Shanghai Jiaotong University, 160# Pujian Road, 
      Pudong, Shanghai, 200127, China. sue_liuwei@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190828
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Adipose Tissue/*cytology
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*pathology
MH  - Humans
MH  - Insulin-Secreting Cells/cytology
MH  - Mesenchymal Stem Cells/*cytology
PMC - PMC6712852
OTO - NOTNLM
OT  - AD-MSCs
OT  - Insulin resistance
OT  - MSC therapy
OT  - T2DM
OT  - beta cell
COIS- The authors declare that they have no competing interests.
EDAT- 2019/08/29 06:00
MHDA- 2020/07/02 06:00
PMCR- 2019/08/28
CRDT- 2019/08/29 06:00
PHST- 2019/08/29 06:00 [entrez]
PHST- 2019/08/29 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2019/08/28 00:00 [pmc-release]
AID - 10.1186/s13287-019-1362-2 [pii]
AID - 1362 [pii]
AID - 10.1186/s13287-019-1362-2 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2019 Aug 28;10(1):274. doi: 10.1186/s13287-019-1362-2.